The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development
Gary J. Kelloff(Unknown), Janet Woodcock(Center for Drug Evaluation and Research), James L. Tatum(National Cancer Institute), Kathryn Z. Guyton(Centre international de recherche sur le cancer), Caroline C. Sigman, George Q. Mills(Center for Drug Evaluation and Research), Ralph Weissleder(Massachusetts General Hospital), Joyce O’Shaughnessy(Baylor University Medical Center), David A. Mankoff(University of Pennsylvania), Howard I. Scher(Memorial Sloan Kettering Cancer Center), Bruce D. Cheson(Center for Cancer and Blood Disorders), William C. Eckelman, Daniel C. Sullivan(Duke Medical Center), Kenneth A. Krohn(University of Washington), Steven M. Larson(Memorial Sloan Kettering Cancer Center), Jeanne M. Link(University of Washington), John M. Hoffman(University of California, Los Angeles)
Cited by 220
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
A clearer vision for in vivo imaging
|Nature Biotechnology|2001|3.8k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k